Category Business

Mirum Pharmaceuticals Scheduled to Attend Upcoming Investor Conferences

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading biopharmaceutical firm specializing in the discovery, acquisition, development, and distribution of innovative therapies for rare and orphan diseases, has revealed its participation in forthcoming investor conferences as follows: For webcast links and additional…

Read MoreMirum Pharmaceuticals Scheduled to Attend Upcoming Investor Conferences

Argonaut Manufacturing Services Boosts Aseptic Pharma Filling with $45M Investment

Argonaut Manufacturing Services Secures $45M Funding for Expanded Pharma Fill / Finish Facility Argonaut Manufacturing Services, a prominent contract development and manufacturing organization in the biopharma and life sciences sectors, has finalized a $45 million financing deal to bolster its…

Read MoreArgonaut Manufacturing Services Boosts Aseptic Pharma Filling with $45M Investment

WuXi Biologics Ireland Site Receives Three ISO Certifications

WuXi Biologics (2269.HK), a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), proudly announces the reception of three esteemed International Organization for Standardization (ISO) certifications at its Ireland facility. These certifications include ISO 50001 for Energy Management Systems, ISO…

Read MoreWuXi Biologics Ireland Site Receives Three ISO Certifications

Sanofi’s Board of Directors Recommends Clotilde Delbos, Anne-Françoise Nesmes, and John Sundy as Independent Directors

Sanofi’s Board of Directors has announced its intentions for the upcoming General Shareholder Meeting on April 30, 2024. The board proposes the renewal of Rachel Duan and Lise Kingo’s terms, alongside the appointment of Clotilde Delbos, Anne-Françoise Nesmes, and John…

Read MoreSanofi’s Board of Directors Recommends Clotilde Delbos, Anne-Françoise Nesmes, and John Sundy as Independent Directors

AbbVie and Tentarix Partner to Innovate Conditional Multi-Specific Biologics for Oncology and Immunology

AbbVie Inc. (NYSE: ABBV) and Tentarix Biotherapeutics have unveiled a significant collaboration aimed at pioneering the development of conditionally-active, multi-specific biologics targeting oncology and immunology. This strategic alliance will harness AbbVie’s extensive experience in these fields alongside Tentarix’s groundbreaking Tentacles™…

Read MoreAbbVie and Tentarix Partner to Innovate Conditional Multi-Specific Biologics for Oncology and Immunology

Diakonos Oncology Appoints Veteran BioPharma Senior Executive, Dr. Paul Lammers, to Board of Directors

Diakonos Oncology Corp. (“Diakonos”), a company in the clinical stage of immuno-oncology, has announced today the appointment of Dr. Paul Lammers, M.D., M.Sc., a distinguished executive with over 35 years of experience in the biotech and pharmaceutical industries, to its…

Read MoreDiakonos Oncology Appoints Veteran BioPharma Senior Executive, Dr. Paul Lammers, to Board of Directors

Lupin Granted U.S. FDA Approval for Minzoya (Levonorgestrel and Ethinyl Estradiol Tablets, USP, and Ferrous Bisglycinate Tablets)

Leading global pharmaceutical company Lupin Limited (Lupin) has announced its receipt of approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for MinzoyaTM (Levonorgestrel and Ethinyl Estradiol Tablets, USP, and Ferrous Bisglycinate…

Read MoreLupin Granted U.S. FDA Approval for Minzoya (Levonorgestrel and Ethinyl Estradiol Tablets, USP, and Ferrous Bisglycinate Tablets)

EffRx Pharmaceuticals Enters Exclusive Licensing and Distribution Partnership with Lupin for BINOSTO® Commercialization in Vietnam & Philippines

EffRx Pharmaceuticals SA, a pharmaceutical company specializing in musculoskeletal and rare diseases medications, has disclosed the signing of an exclusive licensing and distribution arrangement for Binosto® in Vietnam and the Philippines with Lupin Limited (Lupin), a prominent global pharmaceutical company.…

Read MoreEffRx Pharmaceuticals Enters Exclusive Licensing and Distribution Partnership with Lupin for BINOSTO® Commercialization in Vietnam & Philippines

ONO and Numab Forge Collaboration: Advancing Multi-specific Antibody NM49 through Option Agreement

Ono Pharmaceutical Co., Ltd. (Osaka, Japan), led by President and CEO Gyo Sagara, has announced a significant milestone today. The company has formalized an option and collaboration agreement with Numab Therapeutics AG (Horgen, Switzerland), under the leadership of CEO David…

Read MoreONO and Numab Forge Collaboration: Advancing Multi-specific Antibody NM49 through Option Agreement

Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

Today, GSK has announced the successful completion of its acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. As previously announced, this acquisition includes AIO-001, a…

Read MoreBiogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

Takeda Plans Prompt Commencement of Global Phase 3 Trials for TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 by First Half of Fiscal Year 2024

Takeda (TSE:4502/NYSE:TAK) has unveiled positive topline findings from a randomized, double-blind, placebo-controlled, multiple dose Phase 2b trial assessing TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patients diagnosed with narcolepsy type 1. Narcolepsy, a chronic and rare neurological disorder…

Read MoreTakeda Plans Prompt Commencement of Global Phase 3 Trials for TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 by First Half of Fiscal Year 2024

Positive Results for Mosunetuzumab in Japanese Phase I Study: Meeting Primary Endpoint for Relapsed and Refractory Follicular Lymphoma Expansion Cohort

Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) has revealed that the anti-CD20/CD3 bispecific antibody mosunetuzumab has successfully met the primary endpoint of achieving a complete response rate (CRR) in an expansion cohort within the Japanese Phase I study. This study aimed…

Read MorePositive Results for Mosunetuzumab in Japanese Phase I Study: Meeting Primary Endpoint for Relapsed and Refractory Follicular Lymphoma Expansion Cohort